Impact of hepatitis delta virus infection on waiting list outcomes: A competing-risks analysis

Table 2 Baseline characteristics of the delta and non-delta viral infection groups, n (%)/median (interquartile range)

Characteristic	Delta group (n = 174)	Non-delta viral group (n = 92)	SMD	P value
Age (years)	48.0 (42.0-54.0)	53.0 (48.0-58.0)	0.58	< 0.001
Female sex	78 (45)	30 (33)	0.25	0.072
Rural residence	107 (61)	38 (41)	0.41	0.003
BMI (kg/m2)	24.8 (22.8-27.1)	26.4 (24.5-28.1)	0.40	< 0.001
ALT (U/L)	58.1 (39.3-93.1)	48.3 (27.0-77.6)	0.19	0.005
AST (U/L)	76.8 (55.5-116.6)	65.2 (44.0-93.0)	0.23	0.034
Platelets (×109/L)	72.0 (49.0-103.5)	97.8 (71.5-124.2)	0.30	< 0.001
Albumin (g/L)	28.0 (24.9-31.9)	30.8 (25.7-36.0)	0.34	0.004
Total bilirubin (μmol/L)	40.6 (23.5-60.5)	34.2 (20.6-56.5)	0.07	0.198
INR	1.5 (1.3-1.7)	1.4 (1.2-1.6)	0.18	0.063
Creatinine (μmol/L)	66.8 (57.7-75.0)	69.3 (60.3-80.9)	0.29	0.070
Sodium (mmol/L)	138.0 (135.0-140.1)	139.1 (136.0-141.0)	0.22	0.065
Ascites	110 (63)	46 (50)	0.27	0.051
Hepatic encephalopathy	68 (39)	25 (27)	0.26	0.067
Esophageal variceal hemorrhage	35 (20)	25 (27)	0.17	0.190
Hepatocellular carcinoma	31 (18)	18 (20)	0.04	0.854
MELD	15.0 (12.0-17.0)	14.0 (10.0-17.0)	0.15	0.249
MELD-Na	15.0 (12.0-18.8)	15.0 (10.0-17.2)	0.22	0.074
MELD 3.0	16.5 (13.0-20.0)	15.0 (11.0-18.2)	0.29	0.029
Waiting-list time (days)	247.5 (102.5-631)	601.5 (173.5-1936.5)	0.60	< 0.001
Waiting-list death	78 (44.8)	42 (45.7)	0.02	1.00
Transplantation	72 (41.4)	20 (21.7)	0.43	0.002
Delisted	1 (0.6)	5 (5.4)	0.29	0.035
Active in waiting list	23 (13.2)	25 (27.2)	0.35	0.008

¹Non-delta viral: Hepatitis B virus monoinfection + hepatitis B virus/hepatitis C virus + epatitis C virus.

SMD: Standardized mean difference; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; INR: International normalized ratio; MELD: Model for end-stage liver disease; MELD-Na: Model for end-stage liver disease-sodium.